CVS wins upgrade to buy as analyst sees more upside potential than its peers - MarketWatch
1. CVS beat quarterly profit expectations significantly. 2. Analyst upgrades rating to 'buy', raising target price to $75. 3. Stabilization in Aetna and pharmacy-benefits is benefitting CVS's growth. 4. CVS stock rose 45.7% in 2025, outperforming S&P 500. 5. The stock remains undervalued compared to historical levels.